31058-83-0

Basic information

• Product Name: (6-Chloro-pyrimidin-4-yl)-dimethyl-amine
• Synonyms: (6-Chloro-pyrimidin-4-yl)-dimethyl-amine;6-CHLORO-N,N-DIMETHYLPYRIMIDIN-4-AMINE;4-Chloro-6-(dimethylamino)pyrimidine;6-chloro-N,N-dimethylpyrimidin-4-amine(SALTDATA: FREE)
• CAS NO: 31058-83-0
• Molecular Formula: C₆H₈ClN₃
• Molecular Weight: 157.60082
• Product Categories: alkyl chloride
• Mol File: 31058-83-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 102-103 °C
• Boiling Point: 271.407 °C at 760 mmHg
• Flash Point: 117.943 °C
• Appearance: /
• Density: 1.253 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.83±0.10(Predicted)
• CAS DataBase Reference: (6-Chloro-pyrimidin-4-yl)-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Chloro-pyrimidin-4-yl)-dimethyl-amine(31058-83-0)
• EPA Substance Registry System: (6-Chloro-pyrimidin-4-yl)-dimethyl-amine(31058-83-0)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 31058-83-0(Hazardous Substances Data)

Usage

General Description

"(6-Chloro-pyrimidin-4-yl)-dimethyl-amine" is a chemical compound that belongs to the class of organic compounds known as aminopyrimidines and derivatives. This specific compound features a pyrimidine ring, which is a six-member ring with two nitrogen atoms and four carbon atoms, further substituted by a chlorine atom and two methyl groups attached through a nitrogen atom. The detailed information about this compound, such as its physical and chemical properties or its potential uses, is not commonly found in public sources, suggesting it may not be widely used or extensively studied. Detailed investigations may be needed to understand its properties and potential applications.

InChI:InChI=1/C6H8ClN3/c1-10(2)6-3-5(7)8-4-9-6/h3-4H,1-2H3

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 124-40-3 dimethyl amine 

Downstream Products

• 1293938-92-7 4-(dimethylamino)-6-[8-{[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}-(1S,6R)-3,8-diazabicyclo[4.2.0]oct-3-yl]pyrimidine 

Relevant articles and documents

Discovery of BAY-985, a Highly Selective TBK1/IKK? Inhibitor

The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKK? are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles in multiple cellular pathways and, in particular, in inflammation. Herein, we describe our investigations on a family of benzimidazoles and the identification of the potent and highly selective TBK1/IKK? inhibitor BAY-985. BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 and displays antiproliferative efficacy in the melanoma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenograft model.

Regioselective metalations of pyrimidines and pyrazines by using frustrated Lewis pairs of BF3×OEt2 and hindered magnesium- and zinc-amide bases

Born of frustration: Using the frustrated Lewis pairs TMP-metal and BF 3×OEt2 allows the regioselective metalation of pharmaceutically relevant diazines, such as pyrimidines, purines, and pyrazines. These metalations are often complementary to prior deprotonations performed without BF3×OEt2. Especially attractive is a new sequential regioselective full functionalization of the pyrazine scaffold with a bulky (TMS)2CH substituent. Copyright

PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson’s disease, epilepsy, and addiction.